511 related articles for article (PubMed ID: 28831825)
1. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
2. Inhibitors of the PD-1 Pathway in Tumor Therapy.
LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
4. Thymic malignancies: Twisting between autoimmunity and immunotherapy.
Girard N
Lung Cancer; 2017 Aug; 110():68-70. PubMed ID: 28526140
[No Abstract] [Full Text] [Related]
5. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
[No Abstract] [Full Text] [Related]
6. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
Constantinidou A; Alifieris C; Trafalis DT
Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
[TBL] [Abstract][Full Text] [Related]
7. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
8. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
10. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
11. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
Saleh K; Khalifeh-Saleh N; Kourie HR
Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468
[No Abstract] [Full Text] [Related]
12. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
Konstantinidou M; Zarganes-Tzitzikas T; Magiera-Mularz K; Holak TA; Dömling A
Angew Chem Int Ed Engl; 2018 Apr; 57(18):4840-4848. PubMed ID: 29178534
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
17. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
Ullén A
Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
[No Abstract] [Full Text] [Related]
18. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for head and neck cancers: an update and future perspectives.
Doescher J; Laban S; Schuler PJ; Brunner C; Hoffmann TK
Immunotherapy; 2019 May; 11(7):561-564. PubMed ID: 30943860
[No Abstract] [Full Text] [Related]
20. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
